Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares saw unusually-high trading volume on Tuesday . Approximately 14,975,110 shares were traded during trading, an increase of 893% from the previous session’s volume of 1,507,369 shares.The stock last traded at $2.43 and had previously closed at $1.81.

AUPH has been the subject of a number of recent analyst reports. Canaccord Genuity set a $10.00 price target on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 5th. HC Wainwright raised their price objective on shares of Aurinia Pharmaceuticals from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. Leerink Swann reissued an “outperform” rating on shares of Aurinia Pharmaceuticals in a research note on Tuesday. Finally, FBR & Co reissued an “outperform” rating and issued a $9.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $7.75.

The stock’s market capitalization is $84.33 million. The stock has a 50-day moving average price of $3.17 and a 200 day moving average price of $2.78.

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.